ABC008 in Subjects With T-cell Large Granular Lymphocytic Leukemia (T-LGLL)
NCT05532722 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 21
Last updated 2026-05-06
Summary
An open label, ascending dose study for adult subjects with T-cell Large Granular Lymphocytic Leukemia (T-LGLL)
Conditions
- T-cell Large Granular Lymphocytic Leukemia
Interventions
- DRUG
-
ABC008
Given subcutaneous injection
Sponsors & Collaborators
-
Abcuro, Inc.
lead INDUSTRY
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SEQUENTIAL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-09-28
- Primary Completion
- 2025-08-28
- Completion
- 2026-03-31
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Study of Adult T-Cell Leukemia/Lymphoma Among Carriers of HTLV-1
NCT00339638 ·Status: COMPLETED
-
Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma
NCT00049413 ·Status: COMPLETED ·Phase: PHASE2
-
MB-105 in Patients With CD5 Positive T-cell Lymphoma
NCT06534060 ·Status: RECRUITING ·Phase: PHASE2
-
Glucose Intolerance and Diabetes Related to Treatment With Steroids and PEG- Asparaginase in Children and Adolescents With ALL and Lymphoma
NCT05873322 ·Status: RECRUITING
-
Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies
NCT05270057 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
NCT05424822 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
The Leukemia and Lymphoma Society (LLS) T-cells in Blood Cancer and COVID-19
NCT04898985 ·Status: SUSPENDED
-
Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials
NCT03207256 ·Status: TERMINATED ·Phase: PHASE2
-
Study of CD137 Agonist ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma
NCT03707093 ·Status: COMPLETED ·Phase: PHASE1
-
Cell Free DNA in Mature B-cell Lymphoma
NCT04088422 ·Status: RECRUITING
-
Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma
NCT00720135 ·Status: COMPLETED ·Phase: PHASE1
-
Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors
NCT03379259 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
NCT05475925 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Trial of FFP+HDMP+Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia
NCT01670812 ·Status: UNKNOWN ·Phase: PHASE3
-
Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT
NCT00482053 ·Status: TERMINATED ·Phase: PHASE2
-
Personalized Therapy of Precursor Lymphoid Neoplasms
NCT01665001 ·Status: UNKNOWN ·Phase: PHASE2
-
A First-in-human Study to Assess OT-C001 (Amplified/Activated Allogenic Natural Killer Cells) in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma
NCT07044050 ·Status: RECRUITING ·Phase: PHASE1
-
Ex-vivo Expanded γδ T-lymphocytes (OmnImmune®) in Patients With Acute Myeloid Leukaemia (AML)
NCT03790072 ·Status: COMPLETED ·Phase: PHASE1
-
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
NCT04799275 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
NCT01013961 ·Status: TERMINATED ·Phase: PHASE2
-
A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
NCT02220842 ·Status: COMPLETED ·Phase: PHASE1
-
Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma
NCT00556127 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
NCT05512390 ·Status: RECRUITING ·Phase: PHASE1
-
tTF-NGR Phase I Study
NCT02902237 ·Status: COMPLETED ·Phase: PHASE1
-
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
NCT01232556 ·Status: TERMINATED ·Phase: PHASE3